company background image
ERNA

Eterna Therapeutics NasdaqCM:ERNA Stock Report

Last Price

US$4.80

Market Cap

US$24.6m

7D

-3.4%

1Y

-90.2%

Updated

01 Feb, 2023

Data

Company Financials

Eterna Therapeutics Inc.

NasdaqCM:ERNA Stock Report

Mkt Cap: US$24.6m

ERNA Stock Overview

Eterna Therapeutics Inc. develops messenger RNA (mRNA) cell engineering technologies to repair cellular dysfunction and treat therapeutic indications.

ERNA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Eterna Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eterna Therapeutics
Historical stock prices
Current Share PriceUS$4.80
52 Week HighUS$54.80
52 Week LowUS$2.74
Beta0
1 Month Change49.07%
3 Month Change63.82%
1 Year Change-90.18%
3 Year Changen/a
5 Year Changen/a
Change since IPO-94.95%

Recent News & Updates

Brooklyn Immunotherapeutics announces name change to Eterna Therapeutics

Oct 11

Recent updates

Shareholder Returns

ERNAUS BiotechsUS Market
7D-3.4%-0.2%1.7%
1Y-90.2%3.9%-12.5%

Return vs Industry: ERNA underperformed the US Biotechs industry which returned 1.2% over the past year.

Return vs Market: ERNA underperformed the US Market which returned -13.6% over the past year.

Price Volatility

Is ERNA's price volatile compared to industry and market?
ERNA volatility
ERNA Average Weekly Movement18.6%
Biotechs Industry Average Movement12.3%
Market Average Movement6.9%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: ERNA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: ERNA's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a10Matt Angelhttps://eternatx.com

Eterna Therapeutics Inc. develops messenger RNA (mRNA) cell engineering technologies to repair cellular dysfunction and treat therapeutic indications. It offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. The company also develops therapies and medicines using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.

Eterna Therapeutics Inc. Fundamentals Summary

How do Eterna Therapeutics's earnings and revenue compare to its market cap?
ERNA fundamental statistics
Market CapUS$24.61m
Earnings (TTM)-US$28.06m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ERNA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$28.06m
Earnings-US$28.06m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-5.47
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ERNA perform over the long term?

See historical performance and comparison